Journal of Pharmaceutical and Biomedical Sciences

Login
Select Language
Subscription Login to verify subscription
Give a gift subscription
Article Tools
Print this article
Indexing metadata
How to cite item
Finding References
Review policy
Email this article (Login required)
Email the author(Login required)
Post a Comment (Login required)

Study of the Acute Toxicity of the Pharmaceutical Substance of the drug ‘RAPITALAM’, the MGLUR4 Receptors Modulator

Korokin MV, Avdeeva NV, Pokrovskiy MV

Abstract


This article presents the results of the experimental research on the acute toxicity of the pharmaceutical substance of the drug Rapitalam, which is a modulator of metabotropic glutamate receptors. The study was conducted at the center for preclinical studies, Belgorod National Research University. Acute toxicity was studied on non-linear white mice-males weighing 18–22 g. All mice were divided into two groups—experimental and control. To determine the median lethal dose of the solution the test drug was administered to the mice one time intragastrically at doses of 1600, 1800, 2000, 2200 and 2400 mg/kg. The control group animals were given an equivalent amount of the solvent used to prepare the solution of the studied drug. The research has shown a good tolerability of the drug doses several times exceeding the therapeutic dose. According to K.K. Sidorov’s classification, pharmaceutical substance of the drug Rapitalam should be attributed to low-toxic drugs.

Keywords


rapitalam, acute toxicity, Parkinson’s disease, metabotropic glutamate receptors, the mGluR4 receptors modulator

Full Text:

References


Avdeeva NV, Nikitina VA, Kochkarova IS, Litvinova AS. The possibility of administration of glutamate receptors antagonists in the treatment of parkinson’s disease. Res Result Pharmacol Clin Pharmacol. 2016;2:86–94.

Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhi-bits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005;25:3312–3322.

Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005;6:787–798.

Gonder JC, Laber K. A renewed look at laboratory rodent housing and management. ILAR J. 2007;48:29–36.

Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC, 1996.

Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets. 2009;8:475–491.

Petroff OA. GABA and glutamate in the human brain. Neuroscientist 2002;8:562–573.

Watkins JC, Jane DE. The glutamate story. Br J Pharmacol. 2006;147:S100–S108.

Kravchenko DV, Avdeeva NV, Korokin MV. Assessment of the DNA damage level in peripheral blood leukocytes of mice treated orally with Rapitalam in acute and therapeutic doses. Res Result Pharmacol Clin Pharmacol. 2016;2:9–11.

Kudelina OM, Khloponin DP, Maklyakov YS, Zaika VG, Gantsgorn EV. Evaluation efficiency of modern antidepressants by means of quantative pharmaco-EEG. Res Result Pharmacol Clin Pharmacol. 2016;2:12–20.

Avdeeva NV, Kulikov AL, Pokrovskii MV, Avtina TV. Pharmacokinetic studies of new antiparkinsonian drug Rapitalam. Res Result Pharmacol Clin Pharmacol. 2016;2:3–8.

Karaban IN. Use of glutamate receptor blocker amantadine in neurology. Int Neurol J. 2012;2:195–201.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.